Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2023 | Arterial Diseases | Research

Mechanism of salidroside against coronary artery disease by network pharmacology analysis

Authors: Lin Tao, Zhi-Fang Liang, Liu Miao, Yu-Jie Guo, Ye Li, Yan-Li Liu, Dong-Ming Fang, Zhi-Jie Yang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Abstract

Background

Rosenroot (Rhodiola rosea) is a traditional Chinese herbal medicine. It has been used to treat patients with coronary artery disease (CAD). Salidroside is the main active constituent of rosenroot. This study was designed to explore the mechanism of salidroside in treating CAD and its role in angiogenesis in CAD systematically.

Methods

In this study, potential targets related to salidroside and CAD were obtained from public databases. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Disease Ontology (DO) and CellMarker enrichment analyses were performed. The binding of salidroside to angiogenesis-related targets was assessed by PyMOL and Ligplot. Furthermore, the effects of salidroside on collateral circulation were evaluated by correlation analysis of these angiogenesis-related targets with the coronary flow index (CFI), and the influence of salidroside on human umbilical vein endothelial cell (HUVEC) proliferation and migration was assessed.

Results

Eighty-three targets intersected between targets of salidroside and CAD. GO and KEGG analyses indicated that salidroside mainly treated CAD through angiogenesis and anti-inflammatory action. There were 12 angiogenesis-related targets of salidroside in coronary heart disease, among which FGF1 (r = 0.237, P = 2.597E-3), KDR (r = 0.172, P = 3.007E-2) and HIF1A (r = -0.211, P = 7.437E-3) were correlated with the coronary flow index (CFI), and salidroside docked well with them. Finally, cell experiments confirmed that salidroside promoted the proliferation and migration of HUVECs.

Conclusions

This study revealed the potential molecular mechanism of salidroside on angiogenesis in CAD and provided new ideas for the clinical application of salidroside in the treatment of CAD.

Available only for authorised users

Ali Sheikh MS, Alduraywish A, Almaeen A, Alruwali M, Alruwaili R, Alomair BM, et al. Therapeutic value of miRNAs in coronary artery disease. Oxid Med Cell Longev. 2021;2021:8853748.CrossRefPubMedPubMedCentral

Sung PH, Chiang HJ, Li YC, Chiang JY, Chu CH, Shao PL, et al. Baseline factors identified for the prediction of good responders in patients with end-stage diffuse coronary artery disease undergoing intracoronary CD34+ cell therapy. Stem Cell Res Ther. 2020;11(1):324.CrossRefPubMedPubMedCentral

Sung PH, Lee FY, Tong MS, Chiang JY, Pei SN, Ma MC, et al. The five-year clinical and angiographic follow-up outcomes of intracoronary transfusion of circulation-derived CD34+ cells for patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention-phase i clinical trial. Crit Care Med. 2018;46(5):e411–8.CrossRefPubMed

Pries AR, Badimon L, Bugiardini R, Camici PG, Dorobantu M, Duncker DJ, et al. Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. Eur Heart J. 2015;36(45):3134–46.CrossRefPubMed

Cunningham AB, Li HL, Luo P, Zhao WJ, Long XC, Brinckmann JA. There “ain’t no mountain high enough”?: The drivers, diversity and sustainability of China’s Rhodiola trade. J Ethnopharmacol. 2020;252:112379.

Zhuang W, Yue L, Dang X, Chen F, Gong Y, Lin X, et al. Rosenroot (Rhodiola): potential applications in aging-related diseases. Aging Dis. 2019;10(1):134–46.CrossRefPubMedPubMedCentral

Tao H, Wu X, Cao J, Peng Y, Wang A, Pei J, et al. Rhodiola species: A comprehensive review of traditional use, phytochemistry, pharmacology, toxicity, and clinical study. Med Res Rev. 2019;39(5):1779–850.CrossRefPubMed

Zhang X, Xie L, Long J, Xie Q, Zheng Y, Liu K, et al. Salidroside: A review of its recent advances in synthetic pathways and pharmacological properties. Chem Biol Interact. 2021;339:109268.CrossRefPubMed

Zhang Y, Lin F, Yan Z, Chen Z, Chen Y, Zhao Y, et al. Salidroside downregulates microRNA-133a and inhibits endothelial cell apoptosis induced by oxidized low-density lipoprotein. Int J Mol Med. 2020;46(4):1433–42.PubMedPubMedCentral

10.

Jin P, Li LH, Shi Y, Hu NB. Salidroside inhibits apoptosis and autophagy of cardiomyocyte by regulation of circular RNA hsa_circ_0000064 in cardiac ischemia-reperfusion injury. Gene. 2021;767:145075.CrossRefPubMed

11.

Jing C, Sun Z, Xie X, Zhang X, Wu S, Guo K, et al. Network pharmacology-based identification of the key mechanism of Qinghuo Rougan Formula acting on uveitis. Biomed Pharmacother. 2019;120:109381.

12.

Wang X, Wang ZY, Zheng JH, Li S. TCM network pharmacology: A new trend towards combining computational, experimental and clinical approaches. Chin J Nat Med. 2021;19(1):1–11.PubMed

13.

Lv C, Wu X, Wang X, Su J, Zeng H, Zhao J, et al. The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: a general template for research on TCMs. Sci Rep. 2017;7(1):352.CrossRefPubMedPubMedCentral

14.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.CrossRefPubMedPubMedCentral

15.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51.CrossRefPubMedPubMedCentral

16.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.CrossRefPubMed

17.

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.CrossRefPubMedPubMedCentral

18.

Zhang X, Lan Y, Xu J, Quan F, Zhao E, Deng C, et al. Cell Marker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res. 2019;47(D1):D721–8.CrossRefPubMed

19.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.CrossRefPubMedPubMedCentral

20.

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–25.CrossRefPubMedPubMedCentral

21.

Xiong HG, Li H, Xiao Y, Yang QC, Yang LL, Chen L, et al. Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2019;38(1):278.CrossRefPubMedPubMedCentral

22.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–42.CrossRefPubMedPubMedCentral

23.

Chen XL, Tang C, Xiao QL, Pang ZH, Zhou DD, Xu J, et al. Mechanism of Fei-Xian formula in the treatment of pulmonary fibrosis on the basis of network pharmacology analysis combined with molecular docking validation. Evid Based Complement Alternat Med. 2021;2021:6658395.PubMedPubMedCentral

24.

Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578–89.CrossRefPubMed

25.

Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113–31.CrossRefPubMed

26.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.CrossRefPubMed

27.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.CrossRefPubMed

28.

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.CrossRefPubMed

29.

Ni J, Li Y, Li W, Guo R. Salidroside protects against foam cell formation and apoptosis, possibly via the MAPK and AKT signaling pathways. Lipids Health Dis. 2017;16(1):198.CrossRefPubMedPubMedCentral

30.

Chang X, Zhang K, Zhou R, Luo F, Zhu L, Gao J, et al. Cardioprotective effects of salidroside on myocardial ischemia-reperfusion injury in coronary artery occlusion-induced rats and Langendorff-perfused rat hearts. Int J Cardiol. 2016;215:532–44.CrossRefPubMed

31.

Tian H, Ketova T, Hardy D, Xu X, Gao X, Zijlstra A, et al. Endoglin mediates vascular maturation by promoting vascular smooth muscle cell migration and spreading. Arterioscler Thromb Vasc Biol. 2017;37(6):1115–26.CrossRefPubMedPubMedCentral

32.

Dou YQ, Kong P, Li CL, Sun HX, Li WW, Yu Y, et al. Smooth muscle SIRT1 reprograms endothelial cells to suppress angiogenesis after ischemia. Theranostics. 2020;10(3):1197–212.CrossRefPubMedPubMedCentral

33.

Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003;107(4):524–30.CrossRefPubMed

34.

Albrecht-Schgoer K, Schgoer W, Holfeld J, Theurl M, Wiedemann D, Steger C, et al. The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells. Circulation. 2012;126(21):2491–501.CrossRefPubMed

35.

Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107(10):1359–65.CrossRefPubMed

36.

Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther. 2009;17(6):1109–15.CrossRefPubMedPubMedCentral

37.

Ylä-Herttuala S, Bridges C, Katz MG, Korpisalo P. Angiogenic gene therapy in cardiovascular diseases: dream or vision? Eur Heart J. 2017;38(18):1365–71.PubMedPubMedCentral

38.

Tang Y, Vater C, Jacobi A, Liebers C, Zou X, Stiehler M. Salidroside exerts angiogenic and cytoprotective effects on human bone marrow-derived endothelial progenitor cells via Akt/mTOR/p70S6K and MAPK signalling pathways. Br J Pharmacol. 2014;171(9):2440–56.CrossRefPubMedPubMedCentral

39.

Guo Q, Yang J, Chen Y, Jin X, Li Z, Wen X, et al. Salidroside improves angiogenesis-osteogenesis coupling by regulating the HIF-1α/VEGF signalling pathway in the bone environment. Eur J Pharmacol. 2020;884:173394.CrossRefPubMed

40.

Chen P, Liu J, Ruan H, Zhang M, Wu P, Yimei D, et al. Protective effects of salidroside on cardiac function in mice with myocardial infarction. Sci Rep. 2019;9(1):18127.CrossRefPubMedPubMedCentral

41.

Wu Q, Wang J, Tan WLW, Jiang Y, Wang S, Li Q, et al. Extracellular vesicles from human embryonic stem cell-derived cardiovascular progenitor cells promote cardiac infarct healing through reducing cardiomyocyte death and promoting angiogenesis. Cell Death Dis. 2020;11(5):354.CrossRefPubMedPubMedCentral

42.

Li Y, Xue JY, Chen S, Wang C, Sun P, Fu S, et al. LncRNA PVT1 is a novel mediator promoting the angiogenesis response associated with collateral artery formation. Int J Biochem Cell Biol. 2022;151:106294.CrossRefPubMed

Title: Mechanism of salidroside against coronary artery disease by network pharmacology analysis
Authors: Lin Tao
Zhi-Fang Liang
Liu Miao
Yu-Jie Guo
Ye Li
Yan-Li Liu
Dong-Ming Fang
Zhi-Jie Yang
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Arterial Diseases
Published in: BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-023-04027-3

2024 ESC Congress

Springer Medicine

Mechanism of salidroside against coronary artery disease by network pharmacology analysis

Abstract

Background

Methods

Results

Conclusions

2024 ESC Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Anti-cancer effect of nano-encapsulated boswellic acids, curcumin and naringenin against HepG-2 cell line

Terminally ill patients’ and their relatives’ experiences and behaviors regarding complementary and alternative medicine utilization in hospice palliative inpatient care units: a cross-sectional, multicenter survey

Comparison of chitosan nanoparticles containing Lippia citriodora essential oil and citral on the induction of apoptosis in A375 melanoma cells

Management of post-traumatic stress disorder symptoms by yoga: an overview

The effect of lemon inhalation aromatherapy on pain, nausea, as well as vomiting and neurovascular assessment in patients for lower extremity fracture surgery: a randomized trial

Reasons for using traditional and complementary care by people living with HIV on antiretroviral therapy and association with interrupted care: a mixed methods study in Eswatini